Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)
Year: 2016
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Raajit K. Rampal, John O. Mascarenhas, Heidi E. Kosiorek, Dmitriy Berenzon, Elizabeth Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E Salama, Gianni Tognoni, Giuseppe Prosperini, Alessandra Di Lelio, Eliseo Serone, Lorenzo Marfisi, Lonette Sandy, Mark Lawrence Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman
Institutions: Memorial Sloan Kettering Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Hospital of the University of Pennsylvania, Washington University in St. Louis, New York Blood Center, University of Utah, Mario Negri Institute for Pharmacological Research, Columbia University Irving Medical Center, Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2579313886